2016
DOI: 10.1007/s10549-016-3836-6
|View full text |Cite
|
Sign up to set email alerts
|

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

Abstract: Oncotype-DX assay has never been validated for BRCA mutation carriers. This study compares the recurrence score (RS) distribution in BRCA-positive breast cancer patients with that of a general population (GP) of patients and reports their outcomes. Eligible patients were BRCA carriers who performed the Oncotype-DX assay. Two sets of databases were cross-linked: BRCA carriers at Rabin Medical Center and Sheba Medical Center with Oncotype-DX tests performed through Clalit Health Services HMO, from 2003 to 2015. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

9
26
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 31 publications
(36 citation statements)
references
References 26 publications
9
26
0
1
Order By: Relevance
“…To assess if positive lymph nodes tumors are associated with higher RS we combined the LN+ patients in our population and that of Lewin et al . series (again, excluding from the combined analysis our Clalit HMO LN+ patients to prevent overlap); of 14 LN+ patients low RS was found in 3 (21.4%), intermediate in 6 (42.8%) and high RS in 5 of them (35.7%), which is similar to the entire carrier population ( p = 0.81).…”
Section: Resultssupporting
confidence: 92%
See 3 more Smart Citations
“…To assess if positive lymph nodes tumors are associated with higher RS we combined the LN+ patients in our population and that of Lewin et al . series (again, excluding from the combined analysis our Clalit HMO LN+ patients to prevent overlap); of 14 LN+ patients low RS was found in 3 (21.4%), intermediate in 6 (42.8%) and high RS in 5 of them (35.7%), which is similar to the entire carrier population ( p = 0.81).…”
Section: Resultssupporting
confidence: 92%
“…The Oncotype Dx RS distribution of our carrier group and that of three previous studies compared with the general BC population are presented in Table . McAndrew et al .…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Mutation carriers were more likely than age-matched controls to have RS in the intermediate- or high-risk range and overall had higher median RS. This trend has been observed by other authors 58. Significantly, cases were also noted to have tumors of higher grade and lower PgR expression scores.…”
Section: Challenging Clinical Scenariossupporting
confidence: 86%